Using gene therapy to circumvent limitations of TRAIL-based cancer therapy.
作者信息
Yin Ling
机构信息
College of Medicine, University of Florida, Gainesville, FL, USA.
出版信息
Mol Ther Oncol. 2024 Jul 13;32(3):200844. doi: 10.1016/j.omton.2024.200844. eCollection 2024 Sep 19.
Abstract
摘要
相似文献
1
Using gene therapy to circumvent limitations of TRAIL-based cancer therapy.利用基因疗法克服基于TRAIL的癌症治疗的局限性。
Mol Ther Oncol. 2024 Jul 13;32(3):200844. doi: 10.1016/j.omton.2024.200844. eCollection 2024 Sep 19.
2
Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.病毒载体 TRAIL 基因治疗癌症的研究进展。
Cancers (Basel). 2011 Feb 10;3(1):603-20. doi: 10.3390/cancers3010603.
3
TRAIL combinations: The new 'trail' for cancer therapy (Review).TRAIL联合疗法：癌症治疗的新“路径”（综述）
Oncol Lett. 2014 May;7(5):1327-1332. doi: 10.3892/ol.2014.1922. Epub 2014 Feb 27.
4
Role of nanotechnology and gene delivery systems in TRAIL-based therapies.纳米技术和基因递送系统在基于TRAIL的治疗中的作用。
Ecancermedicalscience. 2016 Aug 1;10:660. doi: 10.3332/ecancer.2016.660. eCollection 2016.
5
Bacteriophage-based particles carrying the TNF-related apoptosis-inducing ligand (TRAIL) gene for targeted delivery in hepatocellular carcinoma.基于噬菌体的载有 TNF 相关凋亡诱导配体（TRAIL）基因的颗粒用于肝癌的靶向递释。
Nanoscale. 2024 Mar 28;16(13):6603-6617. doi: 10.1039/d3nr05660k.
6
TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy.间充质干细胞衍生的细胞外囊泡递送肿瘤坏死因子相关凋亡诱导配体是一种有效的抗癌疗法。
J Extracell Vesicles. 2017 Jan 18;6(1):1265291. doi: 10.1080/20013078.2017.1265291. eCollection 2017.
7
TRAIL-based gene delivery and therapeutic strategies.基于 TRAIL 的基因传递和治疗策略。
Acta Pharmacol Sin. 2019 Nov;40(11):1373-1385. doi: 10.1038/s41401-019-0287-8. Epub 2019 Aug 23.
8
TRAIL gene therapy: from preclinical development to clinical application.肿瘤坏死因子相关凋亡诱导配体基因疗法：从临床前研发到临床应用
Curr Gene Ther. 2009 Feb;9(1):9-19. doi: 10.2174/156652309787354612.
9
TRAIL pathway targeting therapeutics.靶向肿瘤坏死因子相关凋亡诱导配体（TRAIL）通路的疗法。
Expert Rev Precis Med Drug Dev. 2018;3(3):197-204. doi: 10.1080/23808993.2018.1476062. Epub 2018 May 28.
10
PRAME/EZH2-mediated regulation of TRAIL: a new target for cancer therapy.PRAME/EZH2 介导的 TRAIL 调节：癌症治疗的新靶点。
Curr Mol Med. 2013 Feb;13(2):296-304. doi: 10.2174/156652413804810727.
引用本文的文献
1
Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application.腺相关病毒在药物研发中的变革：从递送系统到临床应用
J Med Virol. 2025 Jun;97(6):e70447. doi: 10.1002/jmv.70447.
本文引用的文献
1
The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer.TRAIL在癌症细胞凋亡和免疫监视中的作用
Cancers (Basel). 2023 May 13;15(10):2752. doi: 10.3390/cancers15102752.
2
TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase.通过与精氨酸脱氨酶进行基因融合实现TRAIL的稳定及其对癌细胞促凋亡活性的致敏作用。
Oncotarget. 2018 Dec 11;9(97):36914-36928. doi: 10.18632/oncotarget.26398.
3
Getting TRAIL back on track for cancer therapy.让TRAIL在癌症治疗的道路上重回正轨。
Cell Death Differ. 2014 Sep;21(9):1350-64. doi: 10.1038/cdd.2014.81. Epub 2014 Jun 20.
4
Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.针对 Apo2L/TRAIL 系统的自身免疫性疾病和癌症治疗。
Biochem Pharmacol. 2012 Jun 1;83(11):1475-83. doi: 10.1016/j.bcp.2011.12.036. Epub 2012 Jan 2.
5
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.一项在晚期癌症患者中进行的重组人 Apo2L/TRAIL（一种双重促凋亡受体激动剂）的 I 期剂量递增研究。
J Clin Oncol. 2010 Jun 10;28(17):2839-46. doi: 10.1200/JCO.2009.25.1991. Epub 2010 May 10.
Zotero 插件